Compare Medpace Holdings Inc (MEDP) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs AT&T Inc. — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while AT&T Inc. trades at $24.29 (market cap $167.88B). The key difference: AT&T Inc. is far larger — about 9.9× Medpace Holdings Inc's market cap, and AT&T Inc. pays a 4.53% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | T | |
|---|---|---|
Market Cap | $16.90B | $167.88B |
Sector | Technology | Media |
52-Week High | $620.59 | $29.62 |
52-Week Low | $393.42 | $20.49 |
Enterprise Value | $16.52B | $313.20B |
Dividend Yield | — | 4.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
AT&T (T) trades at $24.25, up 0.73% today, with a bullish technical signal from moving averages but overbought RSI near 77. The stock shows strong fundamentals with a P/E of 8.09, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights fiber expansion and AI partnerships, while cash flow improved to $15.12B in 2025.
Outlook is positive with a consensus price target of $27.69, offering 14% upside, supported by dividend yield near 4.7%. Risks include competition from SpaceX's Starlink and high debt levels. Analysts are mixed with 41% buy ratings, suggesting cautious optimism for value investors seeking income and steady growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
